http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S61106509-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39ae96c0ecc22ff90ff986371a3cea0f
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
filingDate 1984-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeacac08424f42faf0844aa7cfb2b8b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3a9a115d1077b33c7ff3624abee5a74
publicationDate 1986-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S61106509-A
titleOfInvention Pharmaceutical composition for nasal cavity application
abstract PURPOSE: To provide the titled composition composed of an antiallergic agent and/or an antihistaminic agent and an aqueous solution of a carboxyvinyl polymer, having a specific viscosity, free from drooping phenomenon and accordingly effective to administer a definite amount of the drug component surely, and giving no undesirable feeling to the body. n CONSTITUTION: The titled composition is composed of (A) an antiallergic agent (e.g. sodium cromoglycate) and/or an antihistaminic agent [e.g. 4-oxo-10-(2,3- dimethylpentanamido)-4H-pyrimido[1,2-C]-quinazoline-3-carboxylic acid sodium salt monohydrate] and (B) an aqueous solution of a carboxyvinyl polymer, and has a viscosity of 60W2,000cps (preferably 300W1,500cps) at 25°C. The con centration of the carboxyvinyl polymer is generally 0.05W0.1%, and when the drug is Na salt, etc., it is 0.1W1%. The viscosity of the composition is preferably adjusted according to the kind of the sprayer, etc. n COPYRIGHT: (C)1986,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002523354-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H02264714-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007501252-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9013284-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0623094-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007538101-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-1051923-C
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8221771-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2860718-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S63101318-A
priorityDate 1984-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450006894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23675763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425539605
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27503
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23681333
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398877
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID236117125

Total number of triples: 28.